APICES acknowledged for its remarkable role in CABOMAYOR clinical trial

We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the CABOMAYOR Trial, a Phase II clinical trial in metastatic renal cell carcinoma (mRCC). This acknowledgement was highlighted in the Journal of Geriatric Oncology.

APICES has contributed extensively to critical aspects throughout the trial, including start-up, coordination, project management, monotoring, pharmacovigilance, data management, biostatistics, and medical writing activities.

This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We sincerely thank Spanish Oncology Genitourinary Group (SOGUG) and Dr. Miguel Ángel Climent for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the CABOMAYOR trial progress and results.

The CABOMAYOR Trial was aimed at evaluating the efficacy tolerability of anticancer drugs in terms of objective response rate in previously untreated fragile older patients with metastatic renal cell carcinoma (mRCC).

For further information about the CABOMAYOR Trial, please visit: Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study – ScienceDirect